Connect Biopharma (NASDAQ:CNTB) Given Buy Rating at HC Wainwright

Connect Biopharma (NASDAQ:CNTB)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Thursday, MarketBeat reports. HC Wainwright also issued estimates for Connect Biopharma’s Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at ($1.16) EPS.

Other equities research analysts have also issued reports about the company. Canaccord Genuity Group dropped their price target on Connect Biopharma from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, September 16th. Weiss Ratings upgraded Connect Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 24th. BTIG Research decreased their price objective on Connect Biopharma to $5.00 and set a “buy” rating on the stock in a report on Wednesday, September 30th. Wall Street Zen upgraded Connect Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Finally, Oppenheimer decreased their price objective on Connect Biopharma to $5.00 and set an “outperform” rating on the stock in a report on Tuesday, September 22nd. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Connect Biopharma presently has a consensus rating of “Moderate Buy” and an average price target of $5.88.

Connect Biopharma Price Performance

Shares of CNTB stock traded up $0.04 during trading hours on Thursday, reaching $0.91. The company had a trading volume of 1,615,787 shares, compared to its average volume of 1,440,792. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.37 and a current ratio of 2.37. The stock has a fifty day moving average of $1.78 and a 200-day moving average of $2.21. The company has a market capitalization of $57.04 million, a price-to-earnings ratio of -0.76 and a beta of -0.16. Connect Biopharma has a 12-month low of $0.85 and a 12-month high of $3.82.

Connect Biopharma (NASDAQ:CNTB) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.04. The company had revenue of $2.75 million during the quarter, compared to analysts’ expectations of $0.74 million. On average, equities analysts anticipate that Connect Biopharma will post -1.09 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC acquired a new position in Connect Biopharma in the first quarter valued at approximately $1,945,000. Bank of America Corp DE acquired a new position in Connect Biopharma during the first quarter worth $41,000. Knott David M Jr lifted its stake in Connect Biopharma by 93.9% during the first quarter. Knott David M Jr now owns 387,835 shares of the company’s stock worth $1,016,000 after purchasing an additional 187,835 shares in the last quarter. Simplify Asset Management Inc. acquired a new position in Connect Biopharma during the first quarter worth $135,000. Finally, Richmond Brothers Inc. acquired a new position in Connect Biopharma during the fourth quarter worth $489,000. 58.72% of the stock is currently owned by institutional investors and hedge funds.

Connect Biopharma Company Profile

Connect Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression.

Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.